Business Update

Entelos completes Cardiovascular PhysioLab platform

Published in Cardiovascular Business Week, February 20th, 2007

Entelos, Inc. (ENTL) a life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced the completion of its Cardiovascular PhysioLab platform, a comprehensive large-scale computer simulation of cholesterol regulation, atherogenesis, and cardiovascular risk.

This newly developed platform enables Entelos to rapidly assess novel drug targets, evaluate combination therapies, identify and interpret biomarker patterns, and predict a drug's long-term clinical efficacy in managing cholesterol, atherosclerosis, and heart disease. The company is already conducting research in partnership with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2007-02-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry